<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00499109</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-15005</org_study_id>
    <secondary_id>105372</secondary_id>
    <secondary_id>IST 12223</secondary_id>
    <secondary_id>CA129343</secondary_id>
    <nct_id>NCT00499109</nct_id>
  </id_info>
  <brief_title>Phase III of RRM1 &amp; ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC</brief_title>
  <official_title>Randomized Phase III Multicenter Trial of RRM1 &amp; ERCC1 Directed Customized Chemotherapy Versus Standard of Care for 1st Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical research study to evaluate if chemotherapy in the experimental arm (E)
      results in a better outcome compared to patients in the standard of care arm (C).

      2:1 randomization to experimental arm (E) or standard arm (C). In arm E, treatment of
      dual-agent chemotherapy will be selected based on RRM1 and ERCC1 expression at the protein
      level. In arm C, treatment of dual-agent chemotherapy will be gemcitabine/carboplatin, i.e.,
      standard of care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before each cycle, blood tests, vital signs, interim medical history, and a physical exam
      will be performed. Patients will be carefully checked so that immediate intervention can be
      initiated should an adverse event (i.e. hypersensitivity) occur.

      The last treatment cycle according to the study will be cycle #6, or any earlier cycle.
      Certain tests will be done within 28 days after the last drug infusion. These include
      physical exam, vital signs, temperature, weight, adverse event evaluation, imaging studies,
      and blood work.

      The study doctor will see the participants every 6 to 8 weeks for at least 12 months after
      they start treatment. After that, the participants will be followed every 3 months for an
      additional 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>6 months</time_frame>
    <description>PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. The data of first documented disease progression or death, as defined by Response Evaluation Criteria In Solid Tumors (RECIST), was recorded, and the time interval from randomization to that date was calculated for each patient and used to generate Kaplan-Meier survival estimates and to calculate the PFS at 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>12 months</time_frame>
    <description>OS at 12 months, determined from the date of randomization. The time interval from randomization to the date of death was calculated for each patient and used to generate Kaplan-Meier survival estimates and to calculate the overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate (RR)</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants per response category. Response to treatment was determined according to Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">275</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>E. Dual Agent Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Arm E.
Patients received treatment according to gene expression strata with four doublet regimens.
Low ERCC1 and Low RRM1 Group - Gemcitabine (G) and Carboplatin (Cb): GCb Group.
Low RRM1 and High ERCC1 Group - Gemcitabine (G) and Docetaxel (D): GD Group.
High RRM1 and Low ERCC1 Group - Docetaxel (D) and Carboplatin (Cb): DCb Group.
High ERCC1 and High RRM1 Group - Vinorelbine (V) and Docetaxel (D): DV Group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C. Standard of Care Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control Arm C: Gemcitabine and Carboplatin (GCb).
All patients in arm C were treated with GCb regardless of gene expression levels. Patients received up to 6 cycles, and no maintenance therapy was allowed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>GD Group: 40 mg/m^2 on days 1 and 8, every 21 days
DCb Group: 75 mg/m^2 on day 1
DV Group: 50 mg/m^2 on days 1 and 15, every 28 days</description>
    <arm_group_label>E. Dual Agent Chemotherapy</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>DV Group: 35 mg/m^2 on days 1 and 15</description>
    <arm_group_label>E. Dual Agent Chemotherapy</arm_group_label>
    <other_name>anti-cancer chemotherapy drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>GCb Group: Area under the curve (AUC) 5 on day 1, every 21 days
DCb Group: AUC 6 on day 1, every 21 days
Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed.</description>
    <arm_group_label>E. Dual Agent Chemotherapy</arm_group_label>
    <arm_group_label>C. Standard of Care Control Arm</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>GCb Group: 1,250 mg/m^2 on days 1 and 8
GD Group: 1,250 mg/m^2 on days 1 and 8
Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed.</description>
    <arm_group_label>E. Dual Agent Chemotherapy</arm_group_label>
    <arm_group_label>C. Standard of Care Control Arm</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed Non-Small Cell Lung Cancer (NSCLC) of adenocarcinoma,
             squamous cell carcinoma, large cell carcinoma, or NSCLC not otherwise specified.
             Patients with suspected NSCLC may enroll prior to the diagnostic biopsy in order to
             obtain both the diagnostic and molecular analysis-required specimen during the same
             procedure. Must have blood work within 30 days prior to biopsy to eliminate any
             unnecessary biopsies on patients that do not qualify (screen failures) due to
             laboratory values that do not meet the inclusion/exclusion criteria. If a patient has
             blood work obtained at an outside facility, this can be utilized for the preliminary
             assessment prior to biopsy, but final inclusion/exclusion values must be obtained
             within 14 days of start of treatment.

          -  Willing to undergo biopsy to enable customization of chemotherapy

          -  Stage IV or IIIB (malignant pleural effusion) NSCLC

          -  Measurable or evaluable disease by Response Evaluation Criteria In Solid Tumors
             (RECIST)

          -  Performance status 0 or 1 by Eastern Cooperative Oncology Group (ECOG) criteria

          -  Adequate bone marrow function as evidenced by the following (assessed within 14 days
             of starting treatment): Absolute neutrophil count &gt;= 1,500/mm³, Platelet count &gt;=
             100,000/mm³, Hemoglobin &gt;= 8.0 gm/dL

          -  Prothrombin time (PT) and activated prothrombin time with thromboplastin and kaolin
             (APTT) within normal laboratory ranges

          -  Serum creatinine &lt;= 1.5 x upper limit of normal (ULN) assessed within 14 days of
             starting treatment

          -  Adequate liver function as evidenced by the following (assessed within 14 days of
             starting treatment): Total bilirubin must be within normal limits; aspartic
             transaminase (AST) and alanine transaminase (ALT) &lt;= 2.5 x ULN with a normal alkaline
             phosphatases; alkaline phosphatases &lt;= 4 x upper limit of normal with normal AST and
             ALT; patients with elevations of alk phos and AST and/or ALT will be excluded

          -  Serum calcium &lt;= 1.1 x ULN

          -  Signed informed consent document

          -  Women of childbearing potential must have a negative pregnancy test. Men with partners
             in the childbearing age group and women of childbearing potential must use effective
             contraception while on treatment and for 6 months thereafter.

          -  Previous surgery for NSCLC (more that 30 days before study entry)

          -  Previous radiotherapy (RT) is allowed if: the time between completion of RT and
             initiation of chemotherapy is at least 7 days; the patient has fully recovered from
             all toxic effects; at least one target lesion or evaluable disease is outside the
             radiation field

          -  Previous chemotherapy allowed if the last dose was administered equal to or greater
             than 12 months ago. This chemotherapy must have been given in an adjuvant or
             neoadjuvant mode prior to or after a complete surgical resection (R0 resection) for a
             NSCLC.

          -  Patients with stable brain metastases will be allowed to enroll. Stable brain
             metastases being defined as no progression of brain metastases 28 days after
             conclusion of definitive treatment as documented by a computed tomography (CT) scan or
             magnetic resonance imaging (MRI) of the brain. Patients with incidentally discovered
             asymptomatic brain metastases may be enrolled and treated with chemotherapy without
             prior brain irradiation if deemed feasible by the treating physician.

        Exclusion Criteria:

          -  Pregnant or lactating

          -  Prior systemic chemotherapy or immunotherapy for advanced NSCLC.

          -  Prior malignancies, except: cured non-melanoma skin cancer curatively treated in situ
             carcinoma of the cervix any other curatively treated malignancy with no evidence of
             disease recurrence for at least 3 years

          -  Presence of uncontrolled brain or leptomeningeal metastases

          -  Peripheral neuropathy or hearing loss of neural origin equal to or greater than grade
             2 by Common Terminology Criteria for Adverse Events (CTCAE) v3.0 except if due to
             trauma

          -  Other serious illness or medical condition, including but not limited to: congestive
             heart failure, myocardial infarction within 6 months, significant neurologic or
             psychiatric disorders that would impact study participation as judged by the treating
             physician or study chair, infection requiring intravenous (IV) antibiotics,
             tuberculosis with ongoing therapy at study entry, superior vena cava syndrome (except
             if controlled with radiation), active peptic ulcer disease, uncontrolled diabetes
             mellitus as judged by the treating oncologist, any contraindication to high dose
             corticosteroid therapy (such as herpes simplex, herpes zoster, hepatitis, or other
             disease)

          -  Hypercalcemia requiring therapeutic intervention

          -  Clinically significant ascites and/or pericardial effusion

          -  Patients with a history of severe hypersensitivity reaction to docetaxel or other
             drugs formulated with polysorbate 80

          -  Concurrent treatment with other investigational drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Williams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Cancer Care &amp; Research/Watson</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leesburg Regional Medical Center</name>
      <address>
        <city>Leesburg</city>
        <state>Florida</state>
        <zip>34748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Sidney Kimmell Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Nebraska Cancer Center</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510-2496</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2947</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Loewenstein</name>
      <address>
        <city>Loewenstein</city>
        <zip>74245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ponce School of Medicine</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2007</study_first_posted>
  <results_first_submitted>September 12, 2013</results_first_submitted>
  <results_first_submitted_qc>February 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 26, 2014</results_first_posted>
  <last_update_submitted>June 25, 2014</last_update_submitted>
  <last_update_submitted_qc>June 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RRM1</keyword>
  <keyword>ERCC1</keyword>
  <keyword>Customized Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Antineoplastic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were registered onto the trial between May 8, 2007 and December 23, 2010. Study sites included Moffitt Cancer Center and 8 other institutions with locations in the United States, Puerto Rico and Germany.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>E. Dual Agent Chemotherapy</title>
          <description>Experimental Arm E.
Patients received treatment according to gene expression strata with four doublet regimens.
Low ERCC1 and Low RRM1 Group - Gemcitabine (G) and Carboplatin (Cb): GCb Group.
Low RRM1 and High ERCC1 Group - Gemcitabine (G) and Docetaxel (D): GD Group.
High RRM1 and Low ERCC1 Group - Docetaxel (D) and Carboplatin (Cb): DCb Group.
High ERCC1 and High RRM1 Group - Vinorelbine (V) and Docetaxel (D): DV Group.</description>
        </group>
        <group group_id="P2">
          <title>C. Standard of Care Control Arm</title>
          <description>Control Arm C: Gemcitabine and Carboplatin (GCb).
All patients in arm C were treated with GCb regardless of gene expression levels. Patients received up to 6 cycles, and no maintenance therapy was allowed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All Participants</population>
      <group_list>
        <group group_id="B1">
          <title>E. Dual Agent Chemotherapy</title>
          <description>Experimental Arm E.
Patients received treatment according to gene expression strata with four doublet regimens.
Low ERCC1 and Low RRM1 Group - Gemcitabine (G) and Carboplatin (Cb): GCb Group.
Low RRM1 and High ERCC1 Group - Gemcitabine (G) and Docetaxel (D): GD Group.
High RRM1 and Low ERCC1 Group - Docetaxel (D) and Carboplatin (Cb): DCb Group.
High ERCC1 and High RRM1 Group - Vinorelbine (V) and Docetaxel (D): DV Group.</description>
        </group>
        <group group_id="B2">
          <title>C. Standard of Care Control Arm</title>
          <description>Control Arm C: Gemcitabine and Carboplatin (GCb).
All patients in arm C were treated with GCb regardless of gene expression levels. Patients received up to 6 cycles, and no maintenance therapy was allowed.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="183"/>
            <count group_id="B2" value="92"/>
            <count group_id="B3" value="275"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.1" lower_limit="42.1" upper_limit="85"/>
                    <measurement group_id="B2" value="62.3" lower_limit="39.6" upper_limit="82.5"/>
                    <measurement group_id="B3" value="63.5" lower_limit="39.6" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. The data of first documented disease progression or death, as defined by Response Evaluation Criteria In Solid Tumors (RECIST), was recorded, and the time interval from randomization to that date was calculated for each patient and used to generate Kaplan-Meier survival estimates and to calculate the PFS at 6 months.</description>
        <time_frame>6 months</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>E. Dual Agent Chemotherapy</title>
            <description>Experimental Arm E.
Patients received treatment according to gene expression strata with four doublet regimens.
Low ERCC1 and Low RRM1 Group - Gemcitabine (G) and Carboplatin (Cb): GCb Group.
Low RRM1 and High ERCC1 Group - Gemcitabine (G) and Docetaxel (D): GD Group.
High RRM1 and Low ERCC1 Group - Docetaxel (D) and Carboplatin (Cb): DCb Group.
High ERCC1 and High RRM1 Group - Vinorelbine (V) and Docetaxel (D): DV Group.</description>
          </group>
          <group group_id="O2">
            <title>C. Standard of Care Control Arm</title>
            <description>Control Arm C: Gemcitabine and Carboplatin (GCb).
All patients in arm C were treated with GCb regardless of gene expression levels. Patients received up to 6 cycles, and no maintenance therapy was allowed.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. The data of first documented disease progression or death, as defined by Response Evaluation Criteria In Solid Tumors (RECIST), was recorded, and the time interval from randomization to that date was calculated for each patient and used to generate Kaplan-Meier survival estimates and to calculate the PFS at 6 months.</description>
          <population>All participants</population>
          <units>estimated percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="45.2" upper_limit="59.8"/>
                    <measurement group_id="O2" value="56.5" lower_limit="47.2" upper_limit="67.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS at 12 months, determined from the date of randomization. The time interval from randomization to the date of death was calculated for each patient and used to generate Kaplan-Meier survival estimates and to calculate the overall survival.</description>
        <time_frame>12 months</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>E. Dual Agent Chemotherapy</title>
            <description>Experimental Arm E.
Patients received treatment according to gene expression strata with four doublet regimens.
Low ERCC1 and Low RRM1 Group - Gemcitabine (G) and Carboplatin (Cb): GCb Group.
Low RRM1 and High ERCC1 Group - Gemcitabine (G) and Docetaxel (D): GD Group.
High RRM1 and Low ERCC1 Group - Docetaxel (D) and Carboplatin (Cb): DCb Group.
High ERCC1 and High RRM1 Group - Vinorelbine (V) and Docetaxel (D): DV Group.</description>
          </group>
          <group group_id="O2">
            <title>C. Standard of Care Control Arm</title>
            <description>Control Arm C: Gemcitabine and Carboplatin (GCb).
All patients in arm C were treated with GCb regardless of gene expression levels. Patients received up to 6 cycles, and no maintenance therapy was allowed.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS at 12 months, determined from the date of randomization. The time interval from randomization to the date of death was calculated for each patient and used to generate Kaplan-Meier survival estimates and to calculate the overall survival.</description>
          <population>All participants</population>
          <units>estimated percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.1" lower_limit="39.3" upper_limit="54"/>
                    <measurement group_id="O2" value="46.6" lower_limit="37.5" upper_limit="58.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate (RR)</title>
        <description>Number of participants per response category. Response to treatment was determined according to Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.</description>
        <time_frame>6 months</time_frame>
        <population>All evaluable participants</population>
        <group_list>
          <group group_id="O1">
            <title>E. Dual Agent Chemotherapy</title>
            <description>Experimental Arm E.
Patients received treatment according to gene expression strata with four doublet regimens.
Low ERCC1 and Low RRM1 Group - Gemcitabine (G) and Carboplatin (Cb): GCb Group.
Low RRM1 and High ERCC1 Group - Gemcitabine (G) and Docetaxel (D): GD Group.
High RRM1 and Low ERCC1 Group - Docetaxel (D) and Carboplatin (Cb): DCb Group.
High ERCC1 and High RRM1 Group - Vinorelbine (V) and Docetaxel (D): DV Group.</description>
          </group>
          <group group_id="O2">
            <title>C. Standard of Care Control Arm</title>
            <description>Control Arm C: Gemcitabine and Carboplatin (GCb).
All patients in arm C were treated with GCb regardless of gene expression levels. Patients received up to 6 cycles, and no maintenance therapy was allowed.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (RR)</title>
          <description>Number of participants per response category. Response to treatment was determined according to Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.</description>
          <population>All evaluable participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 6 months per participant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Experimental: E1</title>
          <description>Docetaxel/Vinorelbine</description>
        </group>
        <group group_id="E2">
          <title>Experimental: E2</title>
          <description>Docetaxel/Carboplatin</description>
        </group>
        <group group_id="E3">
          <title>Experimental: E3</title>
          <description>Gemcitabine/Docetaxel</description>
        </group>
        <group group_id="E4">
          <title>Experimental: E4</title>
          <description>Gemcitabine/Carboplatin</description>
        </group>
        <group group_id="E5">
          <title>Control: C</title>
          <description>Gemcitabine/Carboplatin</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC V3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/Bone Marrow - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Low Hemoglobin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Low Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Low Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Low Platelets</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac General - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pericardial effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia - Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/Visual - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI - Abdomen NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam) - Oral cavity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term - Death NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term - Disease progression NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term - Multi-organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term - Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia: fever - unknown origin W/O clinically or microbiologically documented infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Bleeding - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pain - Bone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pain - Chest wall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pain - Chest/thorax NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pain - Extremity-limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Somnolence/depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Speech impairment (e.g., dysphasia or aphasia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (documented clinically or microbiologically) w/Grade 3 or 4 neutrophils/Lung/pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbiologically) w/Grade 3 or 4 neutrophils/Skin/cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbiologically) w/Grade 3 or 4 neutrophils/Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Bladder (urinary)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Blood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Foreign body</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Lung (pneumonia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Bronchus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Lung (pneumonia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Skin (cellulitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Glucose, serum-low (hypoglycemia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy) - Extraocular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy) - Right-sided</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy) - Whole body/generalized</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Hemorrhage, CNS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Neuropathy: motor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Obstruction, GU - Ureter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" events="10" subjects_affected="8" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory - Bronchopulmonary NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory - Respiratory tract NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising (in absence of Grade 3 or 4 thrombocytopenia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Dermatology/Skin - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Vascular - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTC V3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="86" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Low Hemoglobin</sub_title>
                <counts group_id="E1" events="37" subjects_affected="15" subjects_at_risk="64"/>
                <counts group_id="E2" events="15" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E3" events="8" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E4" events="65" subjects_affected="23" subjects_at_risk="56"/>
                <counts group_id="E5" events="79" subjects_affected="32" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Low Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" events="41" subjects_affected="17" subjects_at_risk="56"/>
                <counts group_id="E5" events="43" subjects_affected="22" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Low Platelets</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E4" events="40" subjects_affected="20" subjects_at_risk="56"/>
                <counts group_id="E5" events="34" subjects_affected="20" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="64"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E3" events="15" subjects_affected="11" subjects_at_risk="37"/>
                <counts group_id="E4" events="17" subjects_affected="15" subjects_at_risk="56"/>
                <counts group_id="E5" events="18" subjects_affected="15" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Low Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="10" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E5" events="13" subjects_affected="6" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Edema: head and neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Thrombotic microangiopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="9" subjects_affected="5" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Auditory/Ear - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Watery eye (epiphora, tearing)</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="64"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Vision-blurred vision</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="28" subjects_affected="26" subjects_at_risk="64"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="26"/>
                <counts group_id="E3" events="17" subjects_affected="13" subjects_at_risk="37"/>
                <counts group_id="E4" events="34" subjects_affected="31" subjects_at_risk="56"/>
                <counts group_id="E5" events="58" subjects_affected="48" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="64"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="37"/>
                <counts group_id="E4" events="18" subjects_affected="17" subjects_at_risk="56"/>
                <counts group_id="E5" events="36" subjects_affected="31" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="64"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="26"/>
                <counts group_id="E3" events="13" subjects_affected="9" subjects_at_risk="37"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="56"/>
                <counts group_id="E5" events="98" subjects_affected="75" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="26" subjects_affected="20" subjects_at_risk="64"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="26"/>
                <counts group_id="E3" events="29" subjects_affected="13" subjects_at_risk="37"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E5" events="14" subjects_affected="12" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="64"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E3" events="15" subjects_affected="10" subjects_at_risk="37"/>
                <counts group_id="E4" events="13" subjects_affected="11" subjects_at_risk="56"/>
                <counts group_id="E5" events="16" subjects_affected="16" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Taste alteration (dysgeusia)</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="64"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="37"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E5" events="14" subjects_affected="13" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam) - Oral cavity</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symptomatic) - Oral cavity</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="64"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="6" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Dysphagia (difficulty swallowing)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Dry mouth/salivary gland (xerostomia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Gastritis (including bile reflux gastritis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="66" subjects_affected="40" subjects_at_risk="64"/>
                <counts group_id="E2" events="28" subjects_affected="20" subjects_at_risk="26"/>
                <counts group_id="E3" events="37" subjects_affected="28" subjects_at_risk="37"/>
                <counts group_id="E4" events="40" subjects_affected="28" subjects_at_risk="56"/>
                <counts group_id="E5" events="81" subjects_affected="66" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" events="12" subjects_affected="9" subjects_at_risk="37"/>
                <counts group_id="E4" events="15" subjects_affected="14" subjects_at_risk="56"/>
                <counts group_id="E5" events="11" subjects_affected="8" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E5" events="12" subjects_affected="12" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="13" subjects_affected="10" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Constitutional Symptoms - Other</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E4" events="7" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" events="12" subjects_affected="10" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Sweating (diaphoresis)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pain - Head/headache</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="64"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E4" events="16" subjects_affected="14" subjects_at_risk="56"/>
                <counts group_id="E5" events="23" subjects_affected="21" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E5" events="17" subjects_affected="16" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pain - Bone</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="12" subjects_affected="8" subjects_at_risk="37"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E5" events="11" subjects_affected="10" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pain - Extremity-limb</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pain - Other</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pain - Chest/thorax NOS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E5" events="10" subjects_affected="8" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pain - Joint</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="64"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E5" events="21" subjects_affected="19" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pain - Throat/pharynx/larynx</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pain - Chest wall</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pain - Muscle</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pain - Oral cavity</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Bleeding - Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="5" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Lung (pneumonia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Sinus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Bladder (urinary)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Lung (pneumonia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="12" subjects_affected="7" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="8" subjects_affected="3" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy) - Whole body/generalized</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy) - Extremity-upper</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy) - Extremity-lower</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="33" subjects_affected="25" subjects_at_risk="64"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="56"/>
                <counts group_id="E5" events="21" subjects_affected="16" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration - Anxiety</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Mood alteration - Depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="30" subjects_affected="21" subjects_at_risk="64"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="37"/>
                <counts group_id="E4" events="28" subjects_affected="18" subjects_at_risk="56"/>
                <counts group_id="E5" events="37" subjects_affected="25" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="64"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="37"/>
                <counts group_id="E4" events="13" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E5" events="25" subjects_affected="22" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory - Nose</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="64"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Voice changes/dysarthria</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hair loss/alopecia (scalp or body)</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="64"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="26"/>
                <counts group_id="E3" events="21" subjects_affected="20" subjects_at_risk="37"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="56"/>
                <counts group_id="E5" events="22" subjects_affected="20" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" events="27" subjects_affected="22" subjects_at_risk="64"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Dermatology/Skin - Other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis (including superficial thrombosis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charles C. Williams, M.D., Study Chair</name_or_title>
      <organization>H. Lee Moffitt Cancer Center and Research Institute</organization>
      <phone>813-745-7282</phone>
      <email>charles.williams@moffitt.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

